US28657F1030 - Common Stock
ELICIO THERAPEUTICS INC
NASDAQ:ELTX (9/6/2024, 8:10:13 PM)
4.23
+0.24 (+6.02%)
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The firm provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The firm's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). The company is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.
ELICIO THERAPEUTICS INC
451 D Street, 5Th Floor
Boston MASSACHUSETTS
P: 18572090050
Employees: 32
Website: https://elicio.com/
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Elicio Therapeutics (NASDAQ:ELTX) just reported results for the second quarter ...
ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
• AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or...
Here you can normally see the latest stock twits on ELTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: